GLP-1 on Dialysis and in ESRD (2026)

If you or someone you care for is on dialysis or has end-stage kidney disease (ESRD) and is considering a GLP-1 drug like Ozempic, Wegovy, Mounjaro or Zepbound, the core questions are: is the dose safe when the kidneys barely work, and what are the real risks? Here is the honest picture. Semaglutide and tirzepatide are not cleared by the kidneys, so blood levels of the drug stay largely the same even in kidney failure — that is why their FDA labels say no dose adjustment is needed for renal impairment, including kidney failure (Ozempic label §8.6 ^[4]; Marbury 2017 ^[2]; Urva 2021 ^[3]). But unchanged drug levels are not the whole story. The pivotal kidney-protection trial, FLOW, excluded patients on dialysis, so the strongest randomized evidence does not directly cover this group (Perkovic 2024 ^[5]). The biggest real-world dataset — a national cohort of 151,649 dialysis patients with diabetes — links GLP-1 use to lower mortality and more transplant waitlisting, but also flags nausea, vomiting and a dehydration pathway to acute kidney injury that matters even more when there is little kidney reserve (Orandi 2025 ^[1]). This article walks through the pharmacology, the label language, the limited data, and the practical cautions — and it is explicit about how thin the ESRD-specific evidence still is.

The honest summary

• Drug levels barely change in kidney failure. Semaglutide and tirzepatide are degraded by enzymes throughout the body, not filtered out by the kidneys. In dedicated studies, exposure in severe renal impairment and ESRD was similar to normal kidney function — so the FDA labels recommend no dose adjustment for any degree of renal impairment, including kidney failure (Marbury 2017^[2]; Granhall 2018^[6]; Urva 2021^[3]; Ozempic label §8.6^[4]).
• The pivotal kidney trial did not include dialysis patients. FLOW showed semaglutide cut major kidney events by 24%, but enrolled people with an eGFR of roughly 25-75 and excluded those on dialysis. So its benefit does not automatically transfer to ESRD (Perkovic 2024^[5]).
• The largest dialysis dataset is observational, and encouraging. In 151,649 incident-dialysis patients with type 2 diabetes, GLP-1 use was associated with greater weight/BMI loss, 23% lower mortality, and a 66% higher chance of being waitlisted for a transplant — with no increase in pancreatitis, biliary disease or medullary thyroid cancer (Orandi 2025^[1]).
• Dehydration and acute kidney injury are the headline caution. Every GLP-1 label now carries a warning: postmarketing reports describe acute kidney injury, sometimes requiring hemodialysis, mostly in people who got dehydrated from nausea, vomiting or diarrhea (Ozempic label §5.6^[4]; Dong 2022^[7]). In someone with little or no residual kidney function, that margin for error is smaller.
• GI side effects can hit harder. A meta-analysis in advanced and end-stage kidney disease found GLP-1s sharply raised nausea and vomiting versus controls — relevant because vomiting drives the dehydration-to-AKI pathway and threatens nutrition in a population already at malnutrition risk (Krisanapan 2024^[6] note: see references).
• Weight loss to qualify for transplant is a real, off-label use. Some transplant programs set a BMI ceiling; the dialysis cohort showing more waitlisting suggests GLP-1s may help candidates reach eligibility — but this is not an FDA-approved indication and should be a specialist decision (Orandi 2025^[1]).
• Bottom line: pharmacology is reassuring, outcome data are thin. The drug doesn't accumulate, but the evidence in dialysis/ESRD is mostly observational and the dehydration risk is amplified. This must be a nephrologist-led, individualized decision — not a self-start.

Why kidney clearance matters less than you'd think

For most drugs, severe kidney disease means the medication piles up in the blood and the dose has to be cut. GLP-1 receptor agonists are different. Semaglutide is a peptide that is broken down by widespread enzymatic proteolysis and beta-oxidation throughout the body, not eliminated intact by the kidneys; tirzepatide behaves similarly. Because the kidney is not the main route of removal, losing kidney function does not cause the drug to accumulate to dangerous levels.

Dedicated pharmacokinetic studies confirm this. In Marbury 2017^[2], a single 0.5 mg dose of injectable semaglutide produced similar overall exposure across normal, mild, moderate, severe renal impairment and ESRD after adjusting for body weight, sex and age. The oral semaglutide study reached the same conclusion (Granhall 2018^[6]). For tirzepatide, Urva 2021^[3] tested a 5 mg dose across the full spectrum of renal function including ESRD and found “no clinically relevant effects of renal impairment” on exposure. That is precisely why the labels say what they say.

What the strongest trial covers — and what it doesn't

The landmark kidney trial for this drug class is FLOW (Perkovic 2024^[5], New England Journal of Medicine). In 3,533 adults with type 2 diabetes and chronic kidney disease, weekly semaglutide reduced the risk of major kidney events — a composite including kidney failure (dialysis or transplant), a 50% drop in eGFR, or kidney/cardiovascular death — by 24%. It was a genuinely practice-changing result for earlier-stage CKD. For the full breakdown, see the FLOW trial explained.

But the entry criteria matter. FLOW enrolled people with an eGFR of roughly 25 to 75 mL/min/1.73 m² and excluded patients already on dialysis. So FLOW tells us semaglutide protects kidneys that still have meaningful function; it does not directly tell us how GLP-1s behave once the kidneys have failed and a person is dialysis-dependent. Extrapolating a slow-the-decline benefit to someone whose kidney decline is already complete is not justified by FLOW. This is the single most important caveat in the dialysis/ESRD conversation: the best randomized evidence stops at the dialysis threshold. For the broader chronic-kidney-disease picture for patients, see the GLP-1 and CKD patient guide.

The dialysis-specific evidence (it's mostly observational)

Because trials excluded dialysis, the best we have is real-world data. The largest is Orandi 2025^[1] in the Clinical Journal of the American Society of Nephrology: a national cohort of 151,649 incident-dialysis patients with type 2 diabetes. GLP-1 users lost more weight (mean change about −4.0 kg vs −1.5 kg) and BMI than nonusers, had roughly 23% lower mortality, and were about 66% more likely to be waitlisted for a kidney transplant. Reassuringly, there was no increased risk of acute pancreatitis, biliary complications or medullary thyroid cancer. One signal to weigh: a 32% higher rate of diabetic retinopathy events, consistent with concerns seen elsewhere with rapid glucose improvement.

A separate systematic review and meta-analysis of GLP-1s in advanced and end-stage kidney disease (Krisanapan 2024^[6] — see note in references) reported improvements in blood glucose, weight and some cardiovascular markers, but a sharply higher rate of nausea and vomiting versus comparators. That GI signal is the practical pivot point: vomiting and diarrhea are exactly what drive the dehydration pathway, and they also threaten adequate nutrition in dialysis patients, who are already vulnerable to protein-energy wasting.

Both findings come with the standard observational caveat: people prescribed a GLP-1 on dialysis may differ in unmeasured ways (healthier, more engaged in care, better controlled) from those who weren't, which can inflate apparent benefit. These are association studies, not randomized proof. Dedicated randomized trials in maintenance dialysis are only now being launched.

The dehydration → acute kidney injury caution, amplified

Every GLP-1 label now carries an acute kidney injury warning. Ozempic's section 5.6 states: “There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea.”^[4] A pharmacovigilance analysis of post-marketing reports confirmed AKI as a reported adverse event across the class (Dong 2022^[7]).

Weight loss to qualify for a transplant

One of the most common real-world reasons a dialysis patient is started on a GLP-1 is to lose enough weight to qualify for a kidney transplant. Many transplant programs decline candidates above a BMI threshold (often around 35-40) because of higher surgical and wound-complication risk. The Orandi cohort's finding that GLP-1 users were markedly more likely to be waitlisted is consistent with these drugs helping candidates reach eligibility (Orandi 2025^[1]). This is a legitimate, increasingly used strategy — but it is off-label (weight management in dialysis/ESRD is not an FDA-approved indication), the supporting data are observational, and it requires coordination between the prescriber, nephrologist and transplant team, including a plan to manage GI side effects and nutrition.

Practical takeaways

• Don't self-start or self-adjust on dialysis or in ESRD. The pharmacology is reassuring, but the safety-and-benefit evidence in this population is mostly observational. This is a nephrologist-led decision.
• “No dose adjustment” is about drug levels, not proven benefit. The labels say levels don't change in kidney failure — they do not establish that the drug is proven safe and effective in dialysis (Ozempic label §8.6^[4]).
• Treat dehydration as the main hazard. Report nausea, vomiting or diarrhea early, and have an explicit hydration and dose-titration plan. The AKI warning is amplified when kidney reserve is low (Ozempic label §5.6^[4]).
• Protect nutrition. Appetite suppression plus GI side effects can worsen the protein-energy wasting that dialysis patients are already prone to — discuss monitoring with the care team.
• If the goal is transplant eligibility, loop in the transplant program. Weight loss to qualify is a recognized off-label use, but it needs the whole team aligned (Orandi 2025^[1]).
• For a fuller dialysis/Stage-5 overview, see the companion article. Read GLP-1 in dialysis and Stage 5 CKD and the general GLP-1 side-effect questions answered.

Bottom line

Semaglutide and tirzepatide are not cleared by the kidneys, so their blood levels stay essentially unchanged even in kidney failure — which is why the FDA labels recommend no dose adjustment for renal impairment, including ESRD (Marbury 2017^[2]; Urva 2021^[3]; Ozempic label §8.6^[4]). But the pivotal kidney trial, FLOW, excluded dialysis patients (Perkovic 2024^[5]), so the strongest randomized evidence stops at the dialysis threshold. What we have in dialysis/ESRD is largely observational: a large national cohort links GLP-1 use to lower mortality, more weight loss and more transplant waitlisting, with a clear nausea/vomiting signal (Orandi 2025^[1]; Krisanapan 2024^[6]). The dehydration-to-acute-kidney-injury warning on every label (Ozempic §5.6^[4]; Dong 2022^[7]) deserves extra weight when kidney reserve is low. The reassuring pharmacology and the thin outcome data together point to one conclusion: in dialysis and ESRD, a GLP-1 can be reasonable, but only as an individualized, nephrologist-led decision with a hydration and nutrition plan — never a self-start.

This article is educational and is not medical advice. Every claim above is sourced to a peer-reviewed study, a published cohort, or the current FDA prescribing information, verified against the live PubMed database and DailyMed before publication. Decisions about any GLP-1 in dialysis or end-stage kidney disease must be made with your nephrologist and prescriber.